Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.

Literature DB >> 25156573

Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.

Scott E Counts, Debomoy K Lahiri¹.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2014 PMID： 25156573 PMCID： PMC5870835 DOI： 10.2174/156720501107140815102453

Source DB: PubMed Journal: Curr Alzheimer Res ISSN： 1567-2050 Impact factor: 3.498

× No keyword cloud information.

31 in total

Review 1. Intravenous immunoglobulin: exploiting the potential of natural antibodies.

Authors: Srini V Kaveri
Journal: Autoimmun Rev Date: 2012-02-12 Impact factor: 9.754

2. Measurement of anti-beta amyloid antibodies in human blood.

Authors: Paul Szabo; Diana M Mujalli; Matthew L Rotondi; Rajal Sharma; Alfred Weber; Hans-Peter Schwarz; Marc E Weksler; Norman Relkin
Journal: J Neuroimmunol Date: 2010-07-31 Impact factor: 3.478

Review 3. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

Authors: Einar M Sigurdsson
Journal: Curr Alzheimer Res Date: 2009-10 Impact factor: 3.498

Review 4. Role of complement systems in IVIG mediated attenuation of cognitive deterioration in Alzheimer's disease.

Authors: Bing Gong; Samara Levine; Scott R Barnum; Giulio M Pasinetti
Journal: Curr Alzheimer Res Date: 2014 Impact factor: 3.498

5. Intravenous immunoglobulin treatment preserves and protects primary rat hippocampal neurons and primary human brain cultures against oxidative insults.

Authors: Debomoy K Lahiri; Balmiki Ray
Journal: Curr Alzheimer Res Date: 2014 Impact factor: 3.498

Review 6. Clinical applications of intravenous immunoglobulins in neurology.

Authors: R A C Hughes; M C Dalakas; D R Cornblath; N Latov; M E Weksler; N Relkin
Journal: Clin Exp Immunol Date: 2009-12 Impact factor: 4.330

7. Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies.

Authors: Tiffany L Sudduth; Abigail Greenstein; Donna M Wilcock
Journal: J Neurosci Date: 2013-06-05 Impact factor: 6.167

8. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.

Authors: Marc E Weksler; Norman Relkin; Rimma Turkenich; Susan LaRusse; Ling Zhou; Paul Szabo
Journal: Exp Gerontol Date: 2002-07 Impact factor: 4.032

9. Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease.

Authors: Johanna Magga; Lakshman Puli; Rea Pihlaja; Katja Kanninen; Suvi Neulamaa; Tarja Malm; Wolfgang Härtig; Jens Grosche; Gundars Goldsteins; Heikki Tanila; Jari Koistinaho; Milla Koistinaho
Journal: J Neuroinflammation Date: 2010-12-07 Impact factor: 8.322

6. Induced dural lymphangiogenesis facilities soluble amyloid-beta clearance from brain in a transgenic mouse model of Alzheimer's disease.

Authors: Ya-Ru Wen; Jun-Hua Yang; Xiao Wang; Zhi-Bin Yao
Journal: Neural Regen Res Date: 2018-04 Impact factor: 5.135

6 in total

Overview of immunotherapy in Alzheimer's disease (AD) and mechanisms of IVIG neuroprotection in preclinical models of AD.

Review 1. Intravenous immunoglobulin: exploiting the potential of natural antibodies.

2. Measurement of anti-beta amyloid antibodies in human blood.

Review 3. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

Review 4. Role of complement systems in IVIG mediated attenuation of cognitive deterioration in Alzheimer's disease.

5. Intravenous immunoglobulin treatment preserves and protects primary rat hippocampal neurons and primary human brain cultures against oxidative insults.

Review 6. Clinical applications of intravenous immunoglobulins in neurology.

7. Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies.

8. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals.

9. Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease.

Review 10. Immunotherapy for Alzheimer's disease: hoops and hurdles.

1. Optimizing early Go/No Go decisions in CNS drug development.

Review 2. Toxic species in amyloid disorders: Oligomers or mature fibrils.

Review 3. The emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence.

Review 4. Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease.

5. Heterogeneity in Cost-Effectiveness Analysis of Vaccination for Mild and Moderate Alzheimer's Disease.

6. Induced dural lymphangiogenesis facilities soluble amyloid-beta clearance from brain in a transgenic mouse model of Alzheimer's disease.